Biokin Pharmaceutical 百利天恒
5 significant filings since 30 May 2026: 4 on buyback and 1 on major contract or bid won. The latest, on 22 Sep 2026: 四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告.
自 30 May 2026 起有 5 份重大公告：buyback 4 份、major contract or bid won 1 份。最新一份（22 Sep 2026）：四川百利天恒药业股份有限公司自愿披露关于全资子公司SystImmune与百时美施贵宝就宜泽康?（伦康依隆妥单抗，BL-B01D1/iza-bren）的全球战略合作协议触发里程碑付款条件的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东吴证券 | 朱国广 | Buy 买入 | 28 Aug 2026 | 2 | — |
| 开源证券 | 余汝意,聂媛媛 | Buy 买入 | 28 Aug 2026 | 2 | — |
| 山西证券 | 邓周宇,魏赟,张智勇 | Buy 买入 | 9 Jun 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 5 reports. 每行为该券商近十二个月的最新研报；5 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。